Pfizer reported a 25 percent drop in sales of its Comirnaty COVID-19 vaccine during the third quarter of 2025, citing narrowed U.S. recommendations and declining public interest in vaccinations. Sales fell to $870 million from $1.16 billion in the same period last year, according to the company. This decline followed the U.S. government’s decision earlier this year to revise vaccine guidelines, which Pfizer attributed to a slower fall vaccination season.
The Centers for Disease Control and Prevention (CDC) updated its recommendations, allowing patients to decide whether to receive COVID-19 vaccines rather than mandating them universally. In May, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced the removal of the COVID vaccine from the CDC’s recommended immunization schedule for healthy children and pregnant women. “I couldn’t be more pleased to announce that, as of today, the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC’s recommended immunization schedule,” he stated at the time.
Supporters of the policy shift, including Dr. Jay Bhattacharya of the National Institutes of Health (NIH) and Dr. Marty Makary of the Food and Drug Administration (FDA), praised the move as “common sense and good science.” Makary noted that several other nations have already ceased recommending the COVID-19 vaccine for children.
Wall Street analysts now predict a 50 percent drop in sales for Moderna’s Spikevax shots, with third-quarter revenue expected to decline sharply. Moderna is set to release its quarterly earnings report later this week.
